
Opinion|Videos|January 28, 2025
Key Unmet Needs in PPF Management
Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and how ongoing research and collaborative efforts may help address these challenges.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What are the key gaps or unmet needs in current management strategies for PPF, and how can ongoing research and collaborative efforts help address these challenges?
Advertisement
Related to this article

Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.

Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.

The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.

Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.

Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.

In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.

Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
2
Bronchiectasis 101: Why permanently dilated airways drive recurrent exacerbations
3
From MFP fallout to AI guardrails: What stood out at AMCP Nexus 2026
4
New pulmonary fibrosis drugs put guidelines in focus, Prusi says | AMCP Nexus 2026
5


